AU2015237270B2 - Compositions and methods related to diagnosis of prostate cancer - Google Patents

Compositions and methods related to diagnosis of prostate cancer Download PDF

Info

Publication number
AU2015237270B2
AU2015237270B2 AU2015237270A AU2015237270A AU2015237270B2 AU 2015237270 B2 AU2015237270 B2 AU 2015237270B2 AU 2015237270 A AU2015237270 A AU 2015237270A AU 2015237270 A AU2015237270 A AU 2015237270A AU 2015237270 B2 AU2015237270 B2 AU 2015237270B2
Authority
AU
Australia
Prior art keywords
antibody
ipsa
capture
subject
tpsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015237270A
Other languages
English (en)
Other versions
AU2015237270A1 (en
Inventor
Hans Lilja
Vincent Linder
Timo Lovgren
Kim Pettersson
Peter T. Scardino
David Steinmiller
Andrew J. Vickers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OPKO Diagnostics LLC
Original Assignee
OPKO Diagnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OPKO Diagnostics LLC filed Critical OPKO Diagnostics LLC
Publication of AU2015237270A1 publication Critical patent/AU2015237270A1/en
Application granted granted Critical
Publication of AU2015237270B2 publication Critical patent/AU2015237270B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
AU2015237270A 2014-03-28 2015-03-27 Compositions and methods related to diagnosis of prostate cancer Active AU2015237270B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972099P 2014-03-28 2014-03-28
US61/972,099 2014-03-28
PCT/US2015/023096 WO2015148979A1 (en) 2014-03-28 2015-03-27 Compositons and methods related to diagnosis of prostate cancer

Publications (2)

Publication Number Publication Date
AU2015237270A1 AU2015237270A1 (en) 2016-10-20
AU2015237270B2 true AU2015237270B2 (en) 2021-09-09

Family

ID=54196462

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015237270A Active AU2015237270B2 (en) 2014-03-28 2015-03-27 Compositions and methods related to diagnosis of prostate cancer

Country Status (24)

Country Link
US (2) US11761962B2 (enExample)
EP (2) EP3123381B1 (enExample)
JP (3) JP6775488B2 (enExample)
KR (1) KR102505543B1 (enExample)
CN (2) CN114740202A (enExample)
AR (1) AR099883A1 (enExample)
AU (1) AU2015237270B2 (enExample)
CA (1) CA2944001C (enExample)
CL (1) CL2016002419A1 (enExample)
DE (1) DE202015009668U1 (enExample)
DK (1) DK3123381T3 (enExample)
EA (1) EA201691952A1 (enExample)
ES (1) ES2964706T3 (enExample)
FI (1) FI3123381T3 (enExample)
HU (1) HUE065029T2 (enExample)
IL (2) IL247981B (enExample)
MX (2) MX392384B (enExample)
MY (1) MY192513A (enExample)
PE (1) PE20170298A1 (enExample)
PL (1) PL3123381T3 (enExample)
PT (1) PT3123381T (enExample)
SG (2) SG11201608035UA (enExample)
TW (1) TWI687688B (enExample)
WO (1) WO2015148979A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103495439B (zh) 2007-05-04 2015-09-16 欧普科诊断有限责任公司 流体连接器和微流体系统
ES2695039T3 (es) 2009-02-02 2018-12-28 Opko Diagnostics, Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
MX362555B (es) 2012-03-05 2019-01-24 Oy Arctic Partners Ab Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica.
US12326453B2 (en) * 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
ES2867798T3 (es) 2015-03-27 2021-10-20 Opko Diagnostics Llc Estándares del antígeno prostático y usos de estos
DK3359189T3 (da) * 2015-10-05 2021-07-05 Fredax Ab Humanized anti psa (5a10) antibodies
US10852310B2 (en) 2015-12-11 2020-12-01 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
CA3006882C (en) 2015-12-29 2023-11-28 Opko Diagnostics, Llc Fluid collection device and related methods
CA3049586A1 (en) * 2017-01-08 2018-07-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Systems and methods for using supervised learning to predict subject-specific pneumonia outcomes
KR102052398B1 (ko) 2018-04-18 2019-12-05 (주)유로테크 전립선암 진단용 바이오마커 및 이의 용도
WO2020205204A1 (en) 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
ES3040560T3 (en) * 2019-10-11 2025-11-03 C The Signs Ltd Diagnostic tool
KR102730255B1 (ko) * 2022-08-12 2024-11-15 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도
CN118629514B (zh) * 2024-08-08 2024-10-29 上海橙帆医药有限公司 序列免疫原性预测方法、装置、电子设备及存储介质

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273643A1 (en) * 2012-03-05 2013-10-17 Arctic Partners Oy Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
WO2013172779A2 (en) * 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
ATE263962T1 (de) 1993-10-28 2004-04-15 I Stat Corp Vorrichtung zur abnahme und einleitung von flüssigkeitsproben
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
AU6788796A (en) 1995-08-03 1997-03-05 Akzo Nobel N.V. Diagnostic device
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
JP4495349B2 (ja) 1999-01-28 2010-07-07 ジェン−プローブ・インコーポレーテッド 癌の遺伝マーカーを生物学的サンプルにおいて検出するための核酸配列
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
US20020076825A1 (en) 2000-10-10 2002-06-20 Jing Cheng Integrated biochip system for sample preparation and analysis
EP1390523B1 (en) 2000-11-20 2007-05-09 Eastern Virginia Medical School Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers
WO2003029427A2 (en) 2001-10-03 2003-04-10 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
WO2003048736A2 (en) 2001-12-05 2003-06-12 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
AU2003242389A1 (en) 2002-05-28 2003-12-12 Jokoh Co., Ltd Immunological chromatograph method test slip reading/quantitative determination device
AU2003256858B2 (en) 2002-08-06 2010-07-01 Aspira Women’s Health Inc. Use of biomarkers for detecting ovarian cancer
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
JP4824540B2 (ja) * 2003-02-07 2011-11-30 ダイアノキュアー インク． サンプル中の前立腺癌を検出する方法
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
EP1535667A1 (en) 2003-11-28 2005-06-01 Sysmex Corporation Analyzer, assay cartridge and analyzing method
US20080107565A1 (en) 2003-12-10 2008-05-08 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Modular Biochip Assembly
US7736890B2 (en) 2003-12-31 2010-06-15 President And Fellows Of Harvard College Assay device and method
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
AU2005209321B2 (en) 2004-01-26 2010-11-18 President And Fellows Of Harvard College Fluid delivery system and method
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
AU2005242724A1 (en) * 2004-05-11 2005-11-24 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US8173433B2 (en) 2004-08-02 2012-05-08 Vermillion, Inc. Platelet biomarkers for cancer
EP1802764A4 (en) 2004-09-17 2010-02-03 Univ Johns Hopkins BIOMARKER FOR BREAST CANCER
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122310A2 (en) 2005-05-11 2006-11-16 The Trustess Of The University Of Pennsylvania System for testing
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
KR20090006837A (ko) 2006-03-24 2009-01-15 페노미넘 디스커버리스 인코포레이티드 전립선 암 진단용 생물표지자 및 그의 제조방법
CN101506376A (zh) 2006-07-03 2009-08-12 埃克森希特医疗股份有限公司 前列腺特异性转录物及其在前列腺癌治疗和诊断中的应用
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
WO2008079095A1 (en) 2006-12-22 2008-07-03 Phadia Ab Novel prostate kallikrein allergen
CN103495439B (zh) 2007-05-04 2015-09-16 欧普科诊断有限责任公司 流体连接器和微流体系统
AU2008251877A1 (en) 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
WO2009029550A2 (en) 2007-08-24 2009-03-05 Singulex, Inc. Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
US20110039284A1 (en) 2007-10-22 2011-02-17 Samuel Norbert Breit Methods of prognosis
US20090226912A1 (en) 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
JP2011521215A (ja) 2008-05-14 2011-07-21 エーテーハー チューリヒ 前立腺癌の診断及び治療のためのバイオマーカー及び薬剤標的発見法、並びにそれを用いて決定されるバイオマーカーアッセイ
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
CA2741034C (en) 2008-10-20 2021-06-22 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
US20110236903A1 (en) 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
EP2376226B1 (en) 2008-12-18 2018-09-12 Opko Diagnostics, LLC Improved reagent storage in microfluidic systems and related articles and methods
US20100168621A1 (en) 2008-12-23 2010-07-01 Neville Thomas B Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
ES2695039T3 (es) 2009-02-02 2018-12-28 Opko Diagnostics, Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
NZ596054A (en) 2009-05-01 2013-07-26 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
WO2010139711A1 (en) * 2009-06-04 2010-12-09 Metanomics Health Gmbh Means and methods for diagnosing prostate carcinomas
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) * 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
SG183867A1 (en) * 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
AU2011239538B2 (en) 2010-04-16 2014-10-23 Opko Diagnostics, Llc Systems and devices for analysis of samples
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9594086B2 (en) 2011-03-22 2017-03-14 The Johns Hopkins University Biomarkers for aggressive prostate cancer
WO2012170776A2 (en) 2011-06-09 2012-12-13 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
JP6072686B2 (ja) 2011-07-21 2017-02-01 和光純薬工業株式会社 血漿中アミノ酸分析用標準液
CA2853669C (en) 2011-10-28 2019-03-12 Fredax Ab Therapeutic agents and uses thereof
US20150044666A1 (en) 2012-01-13 2015-02-12 Iris International Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
BR112014032728A2 (pt) 2012-06-27 2017-11-28 Berg Llc uso de marcadores no diagnóstico e tratamento de câncer de próstata
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
EP2922970B1 (en) 2012-11-20 2018-08-08 Phadia AB Prognostic method for individuals with prostate cancer
ES2667326T3 (es) 2012-11-20 2018-05-10 Phadia Ab Procedimiento para indicar la presencia o no presencia de cáncer de próstata agresivo
CN105980404B (zh) 2013-11-19 2021-01-12 弗雷达克斯有限责任公司 人源化抗激肽释放酶-2抗体
EP3117216B1 (en) 2014-03-11 2023-01-11 Phadia AB Method for detecting a solid tumor cancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
US10217619B2 (en) 2015-03-12 2019-02-26 Thermo Finnigan Llc Methods for data-dependent mass spectrometry of mixed intact protein analytes
ES2867798T3 (es) 2015-03-27 2021-10-20 Opko Diagnostics Llc Estándares del antígeno prostático y usos de estos
JP6873916B2 (ja) 2015-04-29 2021-05-19 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ 前立腺がんの積極的監視のための組成物および方法
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
US20210208146A1 (en) 2018-05-16 2021-07-08 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273643A1 (en) * 2012-03-05 2013-10-17 Arctic Partners Oy Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
WO2013172779A2 (en) * 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A GUPTA ET AL, 2010, British Journal of Cancer, vol. 103, no. 5, pp.708-714. doi: 10.1038/sj.bjc.6605815 *

Also Published As

Publication number Publication date
IL280039B (en) 2021-12-01
EP3299977A1 (en) 2018-03-28
JP2021009157A (ja) 2021-01-28
EP3123381A4 (en) 2018-02-21
JP7506131B2 (ja) 2024-06-25
IL247981A0 (en) 2016-11-30
EA201691952A1 (ru) 2017-05-31
CA2944001A1 (en) 2015-10-01
MX2022002365A (es) 2022-04-06
AR099883A1 (es) 2016-08-24
IL280039A (en) 2021-03-01
DE202015009668U1 (de) 2019-01-21
KR20170008729A (ko) 2017-01-24
JP2017515127A (ja) 2017-06-08
MX392384B (es) 2025-03-24
BR112016022407A2 (pt) 2017-12-12
JP6775488B2 (ja) 2020-10-28
HUE065029T2 (hu) 2024-04-28
FI3123381T3 (fi) 2023-11-27
PE20170298A1 (es) 2017-04-18
TW201621320A (zh) 2016-06-16
JP7256781B2 (ja) 2023-04-12
CN106663149A (zh) 2017-05-10
US20230393137A1 (en) 2023-12-07
IL247981B (en) 2021-02-28
JP2023017841A (ja) 2023-02-07
WO2015148979A8 (en) 2016-01-07
TWI687688B (zh) 2020-03-11
CA2944001C (en) 2023-08-15
CN114740202A (zh) 2022-07-12
PT3123381T (pt) 2023-12-22
MY192513A (en) 2022-08-24
EP3123381A1 (en) 2017-02-01
US11761962B2 (en) 2023-09-19
KR102505543B1 (ko) 2023-03-02
EP3123381B1 (en) 2023-10-11
ES2964706T3 (es) 2024-04-09
PL3123381T3 (pl) 2024-02-26
MX2016012667A (es) 2017-01-09
US20160025732A1 (en) 2016-01-28
CL2016002419A1 (es) 2017-03-31
WO2015148979A1 (en) 2015-10-01
AU2015237270A1 (en) 2016-10-20
SG10201808585TA (en) 2018-11-29
SG11201608035UA (en) 2016-10-28
DK3123381T3 (da) 2023-11-27

Similar Documents

Publication Publication Date Title
US20230393137A1 (en) Compositions and methods related to diagnosis of prostate cancer
US20220399121A1 (en) Systems for providing a probability of prostate cancer risk and/or prostate gland volume, and related methods
US12326453B2 (en) Compositions and methods for active surveillance of prostate cancer
HK1234177A1 (en) Compositions and methods related to diagnosis of prostate cancer
HK1234177B (en) Compositions and methods related to diagnosis of prostate cancer
HK40078292A (en) Compositions and methods related to diagnosis of prostate cancer
EA041331B1 (ru) Композиции и методы, имеющие отношение к диагностике рака предстательной железы
BR112016022407B1 (pt) Métodos, computador, meio de armazenamento e sistemas relacionados ao diagnóstico do câncer de próstata
BR122024013391A2 (pt) Métodos, computador, meio de armazenamento e sistemas relacionados ao diagnóstico do câncer de próstata
BR122024013391B1 (pt) Métodos, computador, meio de armazenamento e sistemas relacionados ao diagnóstico do câncer de próstata

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)